A Single Center Trial of Donor Site Wound Dressings After Split Thickness Skin Grafting.

Donor Site Complication Clinical Trial

Official title:

A Single Centre Randomized Control Trial of Donor Site Wound Dressing After Split Thickness Skin Grafting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06044519
• Other study ID #: Approval/2022/943
• Status: Completed
• Phase: Phase 4
• Start date: August 1, 2022
• Est. completion date: February 28, 2023

Study information

• Verified date: August 2023
• Source: Dow University of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial] is to compare different types of dressings used and there outcomes on STSG donor site wound. The main question[s] it aims to answer are:

• the effectiveness of different donor site dressings and their adverse outcomes

• the satisfaction of patients with the donor site dressing will be observed. Participants will randomly allocated different types of dressings for split thickness skin graft donor site wound which include alginate hydrocolloid hydrofiber silicon film guaze

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• . Patients of aged 18 years and above of either gender underwent single donor-site wounds after split-skin grafting and surface area larger than 10 cm2 were included in the study

Exclusion Criteria:

• Patients on chemotherapy or corticosteroids were excluded from the study. Non-probability consecutive sampling was employed

Related Conditions & MeSH terms

• Donor Site Complication
• Skin Graft Scar

Intervention

Biological:
• different types of dressings
different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Locations

Country	Name	City	State
Pakistan	Dr Ruth KM Pfau civil hospital karachi	Karachi	Sindh

Sponsors (1)

Lead Sponsor	Collaborator
Dow University of Health Sciences

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to asses the effective of dressings by measuring itching , pain and scarring	scaring by POSAS SCORE, pain and itcting by VISUAL ANALOGUE SCAORE.	six month
Secondary	patient satisfaction for scar	likert scale	six months
Secondary	any complications	infection, hypergranulation, allergy	six months